Synopsis
India business, contributing a third of the company’s consolidated revenues, grew on the back of a recovery in non-Covid drug therapies leading to gains for the industry leader. The market is gradually moving back to the pre-Covid levels with Sun growing faster than the industry growth rates.
ET Intelligence Group: India’s largest pharma company, Sun Pharma, welcomed Diwali with the announcement of better-than-expected performance for the quarter to September. Its revenues and net profit each increased 13% over the year-ago level and its operating margin expanded 164 bps to 27.5%.
Growth was driven by strong performance in the domestic market as well as the speciality portfolio in the US. The Sun Pharma stock closed a tad higher at
- FONT SIZE
AbcSmall
AbcMedium
AbcLarge
Sign in to read the full article
You’ve got this Prime Story as a Free Gift
₹399/month
Monthly
PLAN
Billed Amount ₹399
₹208/month
(Save 49%)
Yearly
PLAN
Billed Amount ₹2,499
15
Days Trial
+Includes DocuBay and TimesPrime Membership.
₹150/month
(Save 63%)
2-Year
PLAN
Billed Amount ₹3,599
15
Days Trial
+Includes DocuBay and TimesPrime Membership.
Already a Member? Sign In now
Why ?
Exclusive Economic Times Stories, Editorials & Expert opinion across 20+ sectors
Stock analysis. Market Research. Industry Trends on 4000+ Stocks
Clean experience with
Minimal AdsComment & Engage with ET Prime community Exclusive invites to Virtual Events with Industry Leaders A trusted team of Journalists & Analysts who can best filter signal from noise
